AbbVie (ABBV) Tops Q1 EPS by 9c; Boosts FY15 EPS Outlook

AbbVie (NYSE: ABBV) reported Q1 EPS of $0.94, $0.09 better than the analyst estimate of $0.85. Revenue for the quarter came in at $5.04 billion versus the consensus estimate of $4.98 billion.

AbbVie sees FY2015 EPS of $4.10-$4.30, versus the consensus of $4.19.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
• AeroVironment (AVAV) Tops Q4 EPS by 36c